Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks

Citi analyst Yigal Nochomovitz predicts triple-digit gains for Biomea Fusion (BMEA), a clinical-stage biopharmaceutical company developing treatments for diabetes and obesity. Biomea has two drug candidates in the pipeline, Icovamenib and BMF-650, which target beta-cell function in diabetes and obesity, respectively. In a Phase II study, Icovamenib showed a statistically significant improvement in HbA1c levels compared to placebo, and no serious adverse events were reported.

Biomea is also conducting a Phase I trial for BMF-650, a near-oral GLP-1 receptor agonist, which has demonstrated promising results in preclinical studies. Nochomovitz rates BMEA shares a Buy with a $7 price target, expecting a 410% increase over the next twelve months as the company's pipeline and market potential continue to grow.